1. The promising therapeutic effects of metformin on metabolic reprogramming of cancer-associated fibroblasts in solid tumors
- Author
-
Samaneh Mostafavi, Hamidreza Zalpoor, and Zuhair Mohammad Hassan
- Subjects
Tumor microenvironment ,Myofibroblasts ,Cancer-associated fibroblasts ,Metformin ,Lactic acid ,Stromal cells ,Cytology ,QH573-671 - Abstract
Abstract Tumor-infiltrated lymphocytes are exposed to many toxic metabolites and molecules in the tumor microenvironment (TME) that suppress their anti-tumor activity. Toxic metabolites, such as lactate and ketone bodies, are produced mainly by catabolic cancer-associated fibroblasts (CAFs) to feed anabolic cancer cells. These catabolic and anabolic cells make a metabolic compartment through which high-energy metabolites like lactate can be transferred via the monocarboxylate transporter channel 4. Moreover, a decrease in molecules, including caveolin-1, has been reported to cause deep metabolic changes in normal fibroblasts toward myofibroblast differentiation. In this context, metformin is a promising drug in cancer therapy due to its effect on oncogenic signal transduction pathways, leading to the inhibition of tumor proliferation and downregulation of key oncometabolites like lactate and succinate. The cross-feeding and metabolic coupling of CAFs and tumor cells are also affected by metformin. Therefore, the importance of metabolic reprogramming of stromal cells and also the pivotal effects of metformin on TME and oncometabolites signaling pathways have been reviewed in this study.
- Published
- 2022
- Full Text
- View/download PDF